CEO

Institutional context

GlaxoSmithKline (GSK) is one of the world's largest pharmaceutical companies, headquartered in London. The company in its current form dates to the 2000 merger of Glaxo Wellcome and SmithKline Beecham. From 2000 through 2017, every Chief Executive was male. Walmsley is the first woman to lead a major global pharmaceutical company.

Career path

Walmsley read Classics and Modern Languages at Christ Church, Oxford. She worked for L'Oréal for seventeen years in marketing and general-management roles across France, the United States, the United Kingdom, and China, including General Manager of Consumer Products for L'Oréal China. She joined GSK in May 2010 as President of Consumer Healthcare Europe and became CEO of GSK Consumer Healthcare in March 2015.

Appointment

GSK announced her appointment as the company's next CEO on 20 September 2016. She took office on 1 April 2017, succeeding Sir Andrew Witty.

Tenure

Active. Tenure has included the spinoff of GSK's consumer-healthcare business as Haleon in 2022 (one of the largest UK listings of recent years), strategic refocusing on vaccines and specialty medicines, and the company's substantial role in pandemic-era vaccine and therapeutic development including the adjuvant supply for the Sanofi/GSK COVID-19 vaccine and the development of the RSV vaccine Arexvy.

Cluster context

Walmsley's 2017 appointment precedes the principal cluster window slightly but coincides with the early period of the rate-acceleration. Among the dataset's pharmaceutical and healthcare entries, hers is the most senior corporate role: CEO of one of the largest vaccine manufacturers in the world during the global vaccine deployment of the early 2020s. The pharmaceutical industry has seen no other major-company first-woman CEO appointment since.

Sources

• GlaxoSmithKline — Investor relations and leadership archive
• Financial Times — GSK leadership reporting, 2016–2017